Psychiatry & Neurology, Child & Adolescent Psychiatry · Minneapolis, MN
NPI
1720176308
Since 2006
Specialty
Psychiatry & Neurology, Child & Adolescent Psychiatry
Code 2084P0804X
Group practices
5
Medicare group memberships
Hospitals
1
Hospital affiliations
2450 Riverside Ave SE
Minneapolis, MN, 55455
Phone (612) 365-6777
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,940
201 services
Medicare patients, 2024
72
Average age 57
Drug cost, 2024
$3.5M
555 prescriptions
Company payments, 2025
$0
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peter I Karachunski was code 99214 (office e&m - established), 52 times for 44 patients. In total Peter I Karachunski billed 201 services in 21 codes, and Medicare paid $9,940.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-10-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 52 | 44 | $89.17 | $4,637 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 18 | 13 | $12.49 | $225 |
By year: 2022 $8,320 for 117 services; 2023 $12K for 183 services; 2024 $9,940 for 201 services.
Medicare prescription drug claims, 2024
In 2024, the drug Peter I Karachunski prescribed most often to Medicare patients was Evrysdi (Risdiplam), with 90 prescriptions and refills. In total Peter I Karachunski wrote 555 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Evrysdi Risdiplam | 90 | 92 | Under 11 | $2.6M |
| Pyridostigmine Bromide Generic | 42 | 78 | 13 | $5,908 |
| Prednisone Generic | 36 | 79 | Under 11 | $330 |
| Gabapentin Generic | 30 | 36 | Under 11 | $331 |
| Azathioprine Generic | 28 | 65 | Under 11 | $2,538 |
| Mexiletine Hcl Generic | 24 | 24 | Under 11 | $3,660 |
| Nayzilam Midazolam | 23 | 23 | Under 11 | $35K |
| Lacosamide Generic | 18 | 18 | Under 11 | $438 |
| Acetazolamide Generic | 17 | 19 | Under 11 | $2,045 |
| Mycophenolate Mofetil Generic | 15 | 33 | Under 11 | $1,972 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 14 | 14 | Under 11 | $326 |
| Briviact Brivaracetam | 13 | 13 | Under 11 | $18K |
| Divalproex Sodium Generic | 13 | 13 | Under 11 | $682 |
| Celecoxib Generic | 13 | 13 | Under 11 | $207 |
| Oxcarbazepine Generic | 12 | 12 | Under 11 | $202 |
Brand drugs: - claims; generic drugs: 399 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peter I Karachunski $0 (- in general payments such as food, travel and fees) from 2 companies.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.